openPR Logo
Press release

Cervical Cancer Vaccine Market is Anticipated to be Driven by Global Surge in the Number of Cervical Cancer Patients

08-03-2017 03:02 PM CET | Health & Medicine

Press release from: Transparency Market Research

Cervical Cancer Vaccine Market is Anticipated to be Driven

Cancer in the cervix, which is the lower part of the uterus, is called cervical cancer. Its two primary types are squamous cells cancer and adenocarcinoma. 80% to 90%, i.e., a majority of cervical cancer cases fall under the former category. The latter is less common, constituting 10% to 20% of cases; however, the incidence of adenocarcinoma is rising predominantly in younger girls. Cervical cancer is a common type of cancer occurring in women worldwide. A major cause is infection by human papillomavirus (HPV) which is found in 99% of cervical cancer cases. HPV is sexually transmitted. Around 70% of cervical cancer cases could be attributed to infection caused by two major strains of virus, HPV-16 and HPV-18, which are also termed as high risk HPV types.

Browse Market Research Report @ http://www.transparencymarketresearch.com/cervical-cancer-vaccine-market.html

Cervical cancer can be prevented via widespread immunization with the HPV vaccine, which prevents infection from high-risk HPV strains and also offers protection against the low-risk ones which cause genital warts. The Center for Disease Control and Prevention (CDC) has recommended that the HPV vaccine be administered to girls and boys falling in the age group of 11 to 12 years old. Vaccination at an early stage of life, during teenage, is highly effective. In October 2016, the CDC updated the schedule of the HPV vaccination. It recommends that all teens and adolescents falling between the ages of 9 and 14 should receive two doses of HPV vaccination within a gap of six months.

The rising rate of cervical cancer among women is of particular concern as it is a significantly common type of cancer and a leading cause of death. Its increasing prevalence worldwide is a major driver for the cervical cancer vaccine market. The global surge in the number of cervical cancer patients, especially in developing countries, has motivated key players to develop new vaccines at a low cost. Most vaccines for cervical cancer are in their late stage of clinical development. The rising incidence of cervical cancer has provoked governments and non-profit organizations to take the initiative to create awareness regarding control & prevention of cervical cancer and HPV vaccinations. However, the high cost of the vaccine and the lack of awareness about HPV vaccination in developing countries are major restraining factors for the cervical cancer vaccine market.

The market can be segmented by vaccine type into the bivalent, quadrivalent, and 9-valent varieties. Currently, Gardasil, Gardasil 9, and Cervarix are the only three vaccines approved by the U.S. FDA and commercially available in market. Gardasil and Gardasil 9 are manufactured by Merck & Co., Inc. and Cervarix by GlaxoSmithKline plc. Gardasil is a quadrivalent vaccine which targets four different strains of HPV: HPV-6, HPV-11, HPV-16, and HPV-18.Cervarix is a bivalent vaccine targeting only two high-risk strains of HPV: HPV-16 and HPV-18.

For more information on this report, fill the form @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=24071

Geographically, the global cervical cancer vaccine market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to hold a significant share in the market due to the rising prevalence of cervical cancer and awareness campaigns regarding HPV vaccination by the government and NGOs in the region. Alliances between the public and private sectors for the development of low-cost vaccines, favorable reimbursement policies, and high per capital income levels are also estimated to propel the market in North America. The high incidence of cervical cancer in developing countries and initiatives taken by WHO to develop affordable vaccines for prevention of cervical cancer in low- and middle-income countries are anticipated to drive the market in Asia Pacific, Latin America, and Africa.

Major players operating in the cervical cancer vaccine market include Merck & Co., Inc. and GlaxoSmithKline plc. Another prominent emerging player is ISA Pharmaceuticals B.V., whose immunotherapeutic vaccine is in its phase II trial of clinical development.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cervical Cancer Vaccine Market is Anticipated to be Driven by Global Surge in the Number of Cervical Cancer Patients here

News-ID: 654953 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for HPV

Human Papillomavirus (HPV) Vaccines Market is Thriving Worldwide with Top Compan …
Los Angeles, United State, –The report titled Global Human Papillomavirus (HPV) Vaccines Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Human Papillomavirus (HPV) Vaccines market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete
HPV Vaccines Market 2020-2026 - COVID19 Impact On HPV Vaccines Industry | Top Ke …
HPV Vaccines Market Size, Share & Industry Analysis, By Type (Bivalent and Polyvalent), By Disease Indication (HPV Associated Cancer and Genital Warts), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) and Geography Forecast, 2019-2026. Get Sample Copy Of Report To Know The Impact of Covid19 on this Industry: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-papillomavirus-hpv-vaccines-market-101962 Top Key Players: GSK, Merck. An Overview of the Impact of COVID-19 on HPV Vaccines Market: The emergence of COVID-19 has brought
HPV Testing & PAP Test Market by Test Type (HPV Testing, Follow-up HPV Testing, …
Global HPV Testing & PAP Test Market was valued at USD XX billion in the year 2017. Global HPV Testing & PAP Test market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX billion by the year 2023. Get Free Access to Sample Report @ https://genesismarketinsights.com/Sample_Request/GENRE385 In the Global HPV Testing & PAP Test Market, by region, North America holds the highest market share
Human Papillomavirus (HPV) Therapeutics Market to Reach US$2.34 bn by 2020, Driv …
Human papillomavirus (HPV) and cytomegalovirus (CMV) are viral pathogens affecting individuals of all ages. HPV causes serious sexually transmitted diseases (STDs), while CMV is an opportunistic pathogen affecting immunocompromised individuals such as HIV patients. The global market for HPV and CMV therapeutics is expected to experience a surge due to various macro and micro economic factors. Read the Comprehensive Overview of Human Papillomavirus (HPV) Therapeutics Market:
Cytology and HPV Testing Market: Disparate Levels of Awareness among Patients Re …
Over the years, the level of awareness among the global population regarding the various types of cancer has increased tremendously. The significance of early detection and diagnosis is not lost on them, resulting in the increased adoption of screening tests such as cytology and human papillomavirus (HPV) testing. The global market for cytology and HPV testing is presented with a host of sustained growth opportunities arising mainly from several emerging economies,
New Research: Global Human Papillomavirus (HPV) Market
MarketResearchReports.Biz presents this most up-to-date research on "Human Papillomavirus (HPV)- Epidemiology Forecast To 2023" Latest Report, Human Papillomavirus (HPV) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Human Papillomavirus (HPV) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Human Papillomavirus (HPV) prevalent or incident cases segmented by age, sex and subpopulations. The